Cyclin-Dependent Kinase 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy are effective for ER+/HER2−metastatic breast cancer, yielding markedly higher response rates compared to endocrine therapy alone. This evidence concerns the gene ESR1 and breast carcinoma.